Longman JM, Rix E, Johnston JJ, Passey ME Ambulatory care sensitive chronic conditions: what can we learn from patients about the role of primary health care in preventing admissions? Aust J Prim Health. 2018 Aug 6. doi: 10.1071/PY17191. [Epub ahead of p
Manski-Nankervis JA, Furler J, Audehm R, Blackberry I, Young D Potentially preventable hospitalisations: are they a useful marker of access to and experience of care in general practice among people with type 2 diabetes? Aust J Prim Health. 2015;21(2):21
McKenna G, Rogers A, Walker S, Pope C The influence of personal communities in understanding avoidable emergency department attendance: qualitative study. BMC Health Serv Res. 2020 Sep 21;20(1):887. doi: 10.1186/s12913-020-05705-5.
Pasciak WE, Berg DN, Cherlin E, Fried T, Lipska KJ Qualitative analysis of reasons for hospitalization for severe hypoglycemia among older adults with diabetes. BMC Geriatr. 2021 May 17;21(1):318. doi: 10.1186/s12877-021-02268-w.
Quensell ML, Taira DA, Seto TB, Braun KL, Sentell TL "I Need my Own Place to get Better": Patient Perspectives on the Role of Housing in Potentially Preventable Hospitalizations. J Health Care Poor Underserved. 2017;28(2):784-797. doi: 10.1353/hpu.2017.0
Ridge A, Peterson GM, Seidel BM, Anderson V, Nash R Rural Patients' Perceptions of Their Potentially Preventable Hospitalisation: A Qualitative Study. J Patient Exp. 2022 Jan 4;9:23743735211069825. doi: 10.1177/23743735211069825. eCollection 2022.
Shearer JE, Jenkins CH, Magwood GS, Pope CA Contested Ownership of Disease and Ambulatory-Sensitive Emergency Department Visits for Type 2 Diabetes. Am J Med Sci. 2016 Apr;351(4):400-6. doi: 10.1016/j.amjms.2016.01.007.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
